To ensure you receive your Boston.com e-mails, please add newsletters@boston.com to your address book. If you have trouble reading this e-mail, go to http://www.boston.com/business/ticker_headlines
Daily Business Update Get up-to-the-minute Business Updates More Business News »
Fri. Feb. 10, 2012 Lovebirds may tweet, but thoughtful Romeos don’t Social media such as Twitter may be de rigueur for communications by college students, but one topic is probably best kept off-limits --- tweeting to your chums about the outcome of a hot date. So concludes a new Valentine’s Day survey of 1,200 students from Campus Entertainment, a marketing firm that specializes in targeting college students. “Students clearly prefer to talk about their dates outside of social media channels,” said Campus Entertainment, which has offices in Charlestown.	Advertisement
Ironwood prices stock offering Ironwood Pharmaceuticals Inc., looking to prepare for the launch of a drug to treat irritable bowel syndrome with constipation, announced the pricing of an underwritten public offering of 5.25 million shares of its Class A common stock at a price of $15.09 per share. All shares are being offered by Ironwood, and the gross proceeds are expected to be $79.2 million. The company intends to use some of the net proceeds to prepare for the potential market launch of a drug candidate called linaclotide.
Friendly’s CEO stepping down Friendly’s Ice Cream chief executive Harsha V. Agadi is planning to step down tomorrow and the company’s chief marketing officer is also leaving in several weeks.
iRobot shares plunge on predicted losses from defense cuts Shares of Bedford robot maker iRobot Corp. plunged more than 30 percent to close at $25.17 today, after the company warned of possible losses as decreases in US defense spending reduce demand for its line of military robots.
Celgene to invest $15m in Acetylon Pharmaceuticals Acetylon Pharmaceuticals Inc., a Boston firm developing cancer treatments, announced a $15-million strategic equity investment from Celgene Corp., a New Jersey-based biopharmaceutical company. Under the deal, Celgene does not receive rights or options to Acetylon technology. Acetylon noted that its lead drug candidate has the potential to be combined with a Celegene drug to become an effective drug cocktail treatment for patients with myeloma.
Ex-Takeda executive committed insider trading, SEC claims A former Takeda Pharmaceutical International Inc. executive was accused of using inside information to make more than $63,000 trading in call options, according a lawsuit filed by the Securities and Exchange Commission. Brent Bankosky, a former director in Takeda’s business development group, used non-public information to trade in advance of Takeda’s announcement of transactions involving Cell Genesys Inc. and Millennium Pharmaceuticals Inc., the SEC said in a civil complaint filed today in Manhattan federal court.
Attorneys general agree to $25 billion deal with major US lenders over foreclosures; Mass. to get more than $300 million in help A multistate association of attorneys general, including Massachusetts Attorney General Martha Coakley, has agreed to a $25 billion settlement with five major US banks for their role in the country’s foreclosure crisis, it was announced today.
Ericsson sued by Airvana for $330m Ericsson AB, the world’s largest maker of wireless networks, was sued for more than $330 million by Chelmsford-based Airvana Network Solutions Inc., which says Ericsson misappropriated intellectual property. Ericsson secretly developed a product based on Airvana trade secrets to operate wireless network equipment to avoid paying software licensing fees, Airvana said in a complaint filed in New York state Supreme Court.
Conn.: Public interest a must for NU-NStar deal Connecticut regulators say they won’t approve Northeast Utilities’ proposed multibillion-dollar purchase of Massachusetts electric company NStar unless the companies show the deal would be in the “public interest.” The state Public Utilities Regulatory Authority issued a one-page decision reaffirming the “public interest” standard it has used in previous cases. Connecticut’s attorney general and consumer counsel had asked for the ruling. The authority announced last month that it will review the proposed $4.7 billion purchase, reversing a previous stance against getting involved.
Cubist plans to sue Hospira over its intent to sell generic version of Cubist’s drug Cubist Pharmaceuticals Inc. this morning said it will file a patent infringement lawsuit against generic drug maker Hospira Inc. after being alerted that Hospira has asked regulators for permission to market a generic version of Cubist’s most important drug. Lexington-based Cubist said it received notice from Hospira, based in Lake Forest, Ill., that it has filed an abbreviated new drug application to sell its own version of daptomycin, which Cubist markets under the brand name Cubicin.
Ad agency Allen & Gerritsen will help promote exhibit at Los Angeles Zoo Watertown ad agency Allen & Gerritsen said it has been selected by the Los Angeles Zoo to promote the zoo’s newest exhibit, called LAIR, as in “Living Amphibians, Insects, and Reptiles.” Plans call for the LAIR campaign to use Betty White and Slash (of Guns N’ Roses fame) as celebrity spokespeople. (Both are animal lovers with ties to the zoo, said Allen & Gerritsen.) The campaign will look to build and expand LAIR’s awareness through efforts that include TV, video, print, and out-of-home media.
ADVERTISEMENT Looking to catch the next big game in town? Search from a wide range of Red Sox, Bruins, Celtics and Patriots seats in our exclusive ticket section powered by Ace Ticket. For the best seats to any sporting event in Boston, go to Boston.com Tickets.